<DOC>
	<DOCNO>NCT00918203</DOCNO>
	<brief_summary>The purpose study determine participant untreated locally advanced metastatic non-small cell lung cancer well outcome treat olaratumab combination paclitaxel/carboplatin treat paclitaxel/carboplatin alone .</brief_summary>
	<brief_title>A Study Paclitaxel/Carboplatin With Without Olaratumab ( IMC-3G3 ) Previously Untreated Locally Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>The primary objective study evaluate progression-free survival ( PFS ) previously untreated participant Stage IIIB/IV non-small cell lung cancer ( NSCLC ) treat olaratumab plus paclitaxel carboplatin versus paclitaxel carboplatin first-line metastatic setting .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . The participant histologically cytologically confirm NonSmall Cell Lung Cancer ( NSCLC ) Stage IIIB effusion . Mixed NonSmall Cell Lung Cancer ( NSCLC ) tumor categorize predominant cell type . Primary metastatic site may use histology 2 . For squamous cell histology centrally locate mediastinal mass ( &lt; 3 cm carina ) identify compute tomography scan ( CT ) chest xray , participant must undergo magnetic resonance imaging ( MRI ) chest I.V . contrast CT scan within 3 week randomization , exclude major airway blood vessel invasion ( investigator 's opinion ) cancer 3 . The participant measurable disease ( Tumors within previously irradiate field designate `` nontarget '' lesion unless progression document biopsy obtain confirm persistence least 90 day follow completion radiation therapy 4 . The participant 's Eastern Cooperative Oncology Group ( ECOG ) performance status 01 5 . The participant 's age time study entry ≥ 18 year 6 . The participant adequate hematologic function define absolute neutrophil count ( ANC ) ≥ 1500/μL , hemoglobin ≥ 9.5 g/dL , platelet count ≥ 100,000/μL obtain within 2 week prior randomization 7 . The participant adequate hepatic function define total bilirubin ≤ 1.5 mg/dL , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 × upper limit normal ( ULN ) , ≤ 5 × ULN presence know liver metastasis ) 8 . The participant adequate renal function define serum creatinine ≤ 1.5 × institutional ULN . If creatinine ULN , patient 's creatinine clearance ( CrCl ) ≥ 60 mL/min 9 . The participant urinary protein ≤ 1+ dipstick routine urinalysis ; urine dipstick routine analysis ≥ 2+ , 24hour urine protein must demonstrate &lt; 1 g protein 24 hour allow participation 10 . The participant adequate coagulation function , define international normalized ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) ≤ 5 second ULN receive anticoagulation therapy . Participants fulldose anticoagulation must stable dose oral anticoagulant low molecular weight heparin , therapeutic INR , active bleeding ( define within 14 day randomization ) pathological condition carry high risk bleeding ( eg , tumor involve major vessel know varix ) 11 . Because teratogenicity Olaratumab know , woman childbearing potential ( WOCBP ) sexually active male must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior randomization duration study participation 12 . The participant resolution Grade ≤ 1 National Cancer Institute Common Terminology Criteria Adverse Events , Version 4 ( NCICTCAE v 4.02 ) clinically significant toxic effect prior locoregional therapy , surgery , chemoembolization , anticancer therapy . The exception effect event pertain lab value find elsewhere inclusion criterion . ( For example , criterion # 6 state patient hemoglobin ≥ 9.5 g/dL consider eligible , even though NCICTCAE v 4.02 defines value Grade 2 anemia . ) 13 . The participant life expectancy ≥ 3 month 14 . The participant provide sign informed consent 1 . The participant untreated central nervous system ( CNS ) metastases . Participants eligible clinically stable , steroids cranial irradiation ( whole brain radiation therapy , focal radiation therapy , stereotactic radiosurgery ) end least 2 week prior randomization , surgical resection perform least 4 week prior randomization 2 . The participant radiologically document evidence major blood vessel invasion encasement cancer , intratumor cavitation 3 . The participant receive prior systemic chemotherapy biologic therapy ( eg erlotinib ) Stage IIIB/IV NSCLC outside adjuvant setting . Participants receive prior cytotoxic chemotherapy biologic therapy adjuvant setting exclude base therapy 4 . The participant history another primary cancer , exception ) curatively resect nonmelanomatous skin cancer b ) curatively treated cervical carcinoma situ c ) primary solid tumor treat curative intent , know active disease present , treatment administer last 3 year prior randomization 5 . The participant receive concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy , chemoembolization , target therapy , investigational agent 6 . The participant uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 7 . The participant uncontrolled thrombotic hemorrhagic disorder 8 . The participant history gross hemoptysis ( define bright red blood ≥ 1/2 teaspoon ) within 2 month randomization 9 . The participant serious nonhealing wound , ulcer , bone fracture within 28 day prior randomization 10 . The participant undergone major surgery within 28 day prior randomization 11 . The participant receive adjuvant chemotherapy 21 day prior randomization participate clinical trial experimental agent within 28 day prior randomization 12 . The participant elective plan major surgery perform course trial 13 . The participant peripheral neuropathy ≥ Grade 2 NCICTCAE v 4.02 14 . The participant know human immunodeficiency virus ( HIV ) positivity 15 . The participant , female , pregnant lactate 16 . The participant receive previous therapy agent target platelet derive growth factor ( PDGF ) platelet derive growth factor receptor ( PDGFR ) 17 . The participant know allergy treatment component 18 . The participant history allergic reaction attribute compound chemical biologic composition similar Olaratumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lung neoplasm</keyword>
	<keyword>IMC-3G3</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>PDGFr</keyword>
</DOC>